<DOC>
	<DOCNO>NCT01506193</DOCNO>
	<brief_summary>The purpose study assess immunogenicity safety GSK Biologicals ' investigational measles , mumps , rubella varicella ( MMRV ) vaccine ( GSK208136 , PriorixTetra™ ) co-administered along conjugated Meningococcal C ( MenC ) vaccine ( Meningitec® , Nuron Biotechs ' Vaccine ) healthy child .</brief_summary>
	<brief_title>Immunogenicity Safety Study PriorixTetra™ When Co-administered With Conjugated MenC Vaccine Healthy Children</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representatives ( LAR ) comply requirement protocol . A male female , include , 13 15 month age time first vaccination . Written inform consent obtain parent ( ) / LAR subject . Healthy subject establish medical history clinical examination enter study . Child care . Use investigational nonregistered product study vaccine within 30 day precede dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol start 30 day prior study vaccination/s end 42 day vaccination/s ( Visit 2 ) , exception inactivate influenza ( flu ) vaccine , may give time study , include day study vaccination/s . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous vaccination measles , mumps , rubella , varicella/ herpes zoster and/or N. meningitidis serogroup C. History measles , mumps , rubella , varicella and/or N. meningitidis serogroup C diseases . Known exposure measles , mumps , rubella varicella start 30 day prior enrolment . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . Acute disease and/or fever time enrollment . Documented human immunodeficiency virus ( HIV ) positive subject . Any contraindication state Summary Product Characteristics . Administration immunoglobulins and/or blood product within three month prior first vaccine dose plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>13 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>healthy</keyword>
	<keyword>conjugate</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>child</keyword>
	<keyword>MenC vaccine</keyword>
	<keyword>MMRV vaccine</keyword>
</DOC>